This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings GrowthInvestors Business Daily • 08/15/25
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/06/25
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business UpdatesBusiness Wire • 08/06/25
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's MacroglobulinemiaBusiness Wire • 07/31/25
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC TreatmentBusiness Wire • 07/28/25
The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New HighsInvestors Business Daily • 07/18/25
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?Zacks Investment Research • 07/18/25
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6Business Wire • 07/16/25
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal CarcinomaBusiness Wire • 07/10/25
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug DevelopmentBusiness Wire • 07/10/25
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®Business Wire • 06/25/25
BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its PremiumSeeking Alpha • 06/16/25
U.S. FDA Approves Tablet Formulation of BeOne's BRUKINSA® for All Approved IndicationsBusiness Wire • 06/11/25
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To TripleInvestors Business Daily • 06/05/25
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025Business Wire • 06/02/25
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA's Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025Business Wire • 05/31/25
BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global OncologyBusiness Wire • 05/27/25
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal CancerBusiness Wire • 05/27/25